DK1289535T3 - Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme - Google Patents

Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme

Info

Publication number
DK1289535T3
DK1289535T3 DK01935897T DK01935897T DK1289535T3 DK 1289535 T3 DK1289535 T3 DK 1289535T3 DK 01935897 T DK01935897 T DK 01935897T DK 01935897 T DK01935897 T DK 01935897T DK 1289535 T3 DK1289535 T3 DK 1289535T3
Authority
DK
Denmark
Prior art keywords
apoptotic
treatment
neurodegenerative
patient
devices
Prior art date
Application number
DK01935897T
Other languages
Danish (da)
English (en)
Inventor
Anthony E Bolton
Arkady Mandel
Daniel Sauder
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of DK1289535T3 publication Critical patent/DK1289535T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01935897T 2000-05-25 2001-05-25 Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme DK1289535T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2309424 CA2309424A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
PCT/CA2001/000759 WO2001089537A2 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders

Publications (1)

Publication Number Publication Date
DK1289535T3 true DK1289535T3 (da) 2007-11-05

Family

ID=4166243

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01935897T DK1289535T3 (da) 2000-05-25 2001-05-25 Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme

Country Status (12)

Country Link
US (3) US7132285B2 (OSRAM)
EP (1) EP1289535B1 (OSRAM)
JP (1) JP2003534282A (OSRAM)
AT (1) ATE366581T1 (OSRAM)
AU (1) AU2001261987A1 (OSRAM)
CA (1) CA2309424A1 (OSRAM)
DE (1) DE60129322T2 (OSRAM)
DK (1) DK1289535T3 (OSRAM)
ES (1) ES2290134T3 (OSRAM)
PT (1) PT1289535E (OSRAM)
TW (1) TWI239843B (OSRAM)
WO (1) WO2001089537A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
EP1429727A1 (en) * 2001-09-18 2004-06-23 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20060008517A1 (en) * 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
US11000548B2 (en) * 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
JP6858128B2 (ja) 2015-02-18 2021-04-14 エンリヴェックス セラピューティクス リミテッド 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
CN113106053A (zh) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
EP3416661A4 (en) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696092B2 (en) * 1992-02-07 2004-02-24 Vasogen Ireland Limited Endothelial lining effects and treatment of vasospastic disorders
CA2129630C (en) * 1992-02-07 2003-09-23 Anthony E. Bolton Method of increasing the concentration of nitric oxide in blood
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
HK1043726B (en) 1999-01-12 2004-10-15 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal Pre-conditioning against cell death
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
MXPA02008740A (es) 2000-03-07 2003-02-24 E F P Floor Prod Fussboeden Conexion mecanica de panel.
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
CA2468197A1 (en) * 2001-11-29 2003-06-05 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
US7255880B2 (en) * 2003-04-03 2007-08-14 Vasogen Ireland Limited Treatment of endothelin-related disorders

Also Published As

Publication number Publication date
TWI239843B (en) 2005-09-21
DE60129322T2 (de) 2008-03-13
US7132285B2 (en) 2006-11-07
EP1289535A2 (en) 2003-03-12
HK1055080A1 (en) 2003-12-24
ATE366581T1 (de) 2007-08-15
DE60129322D1 (de) 2007-08-23
WO2001089537A3 (en) 2002-08-01
US20070087010A1 (en) 2007-04-19
CA2309424A1 (en) 2001-11-25
PT1289535E (pt) 2007-10-19
ES2290134T3 (es) 2008-02-16
US20020044924A1 (en) 2002-04-18
US20080131416A1 (en) 2008-06-05
EP1289535B1 (en) 2007-07-11
JP2003534282A (ja) 2003-11-18
WO2001089537A2 (en) 2001-11-29
AU2001261987A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
DK1289535T3 (da) Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme
HU9300636D0 (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
Gileva et al. Hirudotherapy
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
PT2111868E (pt) Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos
DK0796103T3 (da) Anvendelse af røgelse til behandling af Alzheimer-sygdommen
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
BR0307041A (pt) Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
DE69921678D1 (de) Zusammensetzung enthaltend di- und trinatriumsalze von echinochrome zur behandlung von augenerkrankungen
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DK1251850T3 (da) Anvendelse af et kombinationspræparat i cancerbehandling
DE60305534D1 (de) Verwendung von docosahexaensäure als wirkstoff bei der behandlung von lipodystrophie
WO2001089538A3 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
DK1143976T3 (da) Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
Viebahn-Haensler Milestones of medical ozone
Wiggins et al. Hypnosis with two pedicle graft cases
Rosen et al. Intention myoclonus—diazepam and phenobarbital treatment
MX9503363A (es) N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1.
BROCKWAY THE TREATMENT OF OSTEOMYELITIS IN THE WARM SALT-WATER POOL
Randall Allopurinol
DILIXAT et al. Effects of Sand Bathing on Heart Rate, Blood Pressure, Body Temperature, Weight and Rheumatiod Arthritis at Turpan, China